Regulus Therapeutics Inc [RGLS] stock prices are up 16.28% to $1.50 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RGLS shares have gain 10.29% over the last week, with a monthly amount glided 10.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on March 27, 2025, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $6 from $3. Previously, Oppenheimer started tracking the stock with Outperform rating on August 02, 2024, and set its price target to $7. On March 18, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $6 on the stock. B. Riley FBR Inc. started tracking the stock assigning a Neutral rating and suggested a price target of $1 on March 28, 2018. Leerink Partners initiated its recommendation with a Outperform and recommended $2 as its price target on January 05, 2018. Chardan Capital Markets reiterated a Buy rating for this stock on June 13, 2017, and downed its price target to $2.50. In a note dated March 06, 2017, Wedbush reiterated an Outperform rating on this stock and revised its target price from $8 to $6.
The stock price of Regulus Therapeutics Inc [RGLS] has been fluctuating between $0.83 and $3.00 over the past year. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $1.50 at the most recent close of the market.
Analyzing the RGLS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.5 and Total Capital is -0.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2103 points at the first support level, and at 0.9207 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9198, and for the 2nd resistance point, it is at 2.3397.
Ratios To Look Out For
It’s worth pointing out that Regulus Therapeutics Inc [NASDAQ:RGLS]’s Current Ratio is 10.52. On the other hand, the Quick Ratio is 10.52, and the Cash Ratio is 5.14.
Transactions by insiders
Recent insider trading involved Hagan Joseph P, Chief Executive Officer, that happened on Jan 30 ’25 when 50000.0 shares were purchased. Director, BALTIMORE DAVID completed a deal on Jan 30 ’25 to buy 19610.0 shares. Meanwhile, Sr. VP & General Counsel Aker Christopher Ray sold 38547.0 shares on Jan 13 ’25.
